Company profile
Mitera Biosciences
Reimagining the future of immunotherapy for autoimmune diseases and transplant rejection
- Industry
- Biotechnology Research
- Employees
- 1
- Headquarters
- Bellevue, Washington
- Founded
- 2024
- LinkedIn followers
- 169
- Office locations
- 1
Mitera Biosciences company summary
Mitera Biosciences is a company in the Biotechnology Research industry, headquartered in Bellevue, Washington, founded in 2024. On LinkedIn the company has around 1 employees and 169 followers. Its listed specialties include biotechnology, autoimmune diseases, immunology, autoimmune.
What technology does Mitera Biosciences use?
No technologies detected yet. Warmrank rechecks company websites on a rolling basis.
About Mitera Biosciences
At Mitera Biosciences we are developing unique therapeutic candidates with a novel mechanism of action leveraging at least three key features: (1) impairment of effector T cells (Teffs); (2) proliferation of regulatory T cells (Tregs); and (3) downregulation of B cell activation, proliferation, and antibody production. Tregs are a key component in maintaining a healthy and balanced innate immune system and transplant recipients and autoimmune disease patients suffer from a deficiency of Tregs. However, inducing Tregs alone is not likely sufficient to have an immediate impact on disease and therefore modulating Teffs and B cell mechanisms simultaneously presents a novel approach. Leveraging intellectual property exclusively licensed from world renowned Cedars Sinai Medical Center (Los Angeles, California), our drug candidates are derived from a natural human protein which is produced by the human placenta during pregnancy and is also abundantly expressed in the thymus. Recent data suggest this protein may be an important regulator of maternal-fetal tolerance during pregnancy. We felt it would be an important agent to investigate as a potential therapeutic for prevention of transplant rejection and a treatment for autoimmune diseases, conditions which are known to be perpetuated by Teff and suppressed by Treg cells. If successful in future clinical studies, our therapeutic drug candidates could help patients in need without the toxicity of today’s mainstay immunosuppressant drugs such as calcineurin inhibitors and mycophenolic acid. We are also exploring this novel axis of immunobiology for the development of additional therapeutic drug programs.
Specialties
Where is Mitera Biosciences located?
Mitera Biosciences lists 1 location.
Compare companies similar to Mitera Biosciences
More companies in Biotechnology Research.
| Company | Industry | Employees | Founded | Headquarters |
|---|---|---|---|---|
Mitera Biosciences miterabio.com | Biotechnology Research | 1 | 2024 | Bellevue, Washington |
 Thermo Fisher Scientific thermofisher.com | Biotechnology Research | 100,779 | - | Waltham, MA |
 Amgen amgen.com | Biotechnology Research | 41,028 | 1980 | Thousand Oaks, CA |
 Biogen biogen.com | Biotechnology Research | 7,742 | - | Cambridge, MA |
 Biocon biocon.com | Biotechnology Research | 11,902 | - | Bangalore, Karnataka |
| Biotechnology Research | 28,679 | - | Bethesda, MD | |
 Genentech gene.com | Biotechnology Research | 18,296 | 1976 | South San Francisco, California |
 Eurofins eurofins.com | Biotechnology Research | 24,928 | - | Luxembourg, Luxembourg |
 Gilead Sciences gilead.com | Biotechnology Research | 14,743 | - | Foster City, CA |
 Syneos Health syneoshealth.com | Biotechnology Research | 23,772 | - | Morrisville, NC |
 Moderna modernatx.com | Biotechnology Research | 6,238 | 2010 | Cambridge, Massachusetts |
Frequently asked questions about Mitera Biosciences
What does Mitera Biosciences do?
At Mitera Biosciences we are developing unique therapeutic candidates with a novel mechanism of action leveraging at least three key features: (1) impairment of effector T cells (Teffs); (2) proliferation of regulatory T cells (Tregs); and (3) downregulation of B cell activation, proliferation, and antibody production. Tregs are a key component in maintaining a healthy and balanced innate immune system and transplant recipients and autoimmune disease patients suffer from a deficiency of Tregs. However, inducing Tregs alone is not likely sufficient to have an immediate impact on disease and therefore modulating Teffs and B cell mechanisms simultaneously presents a novel approach. Leveraging intellectual property exclusively licensed from world renowned Cedars Sinai Medical Center (Los Angeles, California), our drug candidates are derived from a natural human protein which is produced by the human placenta during pregnancy and is also abundantly expressed in the thymus. Recent data suggest this protein may be an important regulator of maternal-fetal tolerance during pregnancy. We felt it would be an important agent to investigate as a potential therapeutic for prevention of transplant rejection and a treatment for autoimmune diseases, conditions which are known to be perpetuated by Teff and suppressed by Treg cells. If successful in future clinical studies, our therapeutic drug candidates could help patients in need without the toxicity of today’s mainstay immunosuppressant drugs such as calcineurin inhibitors and mycophenolic acid. We are also exploring this novel axis of immunobiology for the development of additional therapeutic drug programs.
How many employees does Mitera Biosciences have?
Mitera Biosciences has around 1 employees on LinkedIn.
Where is Mitera Biosciences headquartered?
Mitera Biosciences is headquartered in Bellevue, Washington.
When was Mitera Biosciences founded?
Mitera Biosciences was founded in 2024.
Build a lead list from companies like Mitera Biosciences
Describe your ICP or import a CSV. Warmrank finds matching companies, enriches contacts with verified emails, and tracks every lead.